Shares of AcelRx Pharmaceuticals ACRX decreased in after-market trading after the company reported Q1 results.
Earnings per share rose 60.00% year over year to ($0.08), which were in line with the estimate of ($0.08).
Revenue of $511,000 up by 32.38% year over year, which missed the estimate of $1,060,000.
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: May 17, 2021
Time: 04:30 PM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/406/41005
Recent Stock Performance
Company's 52-week high was at $2.94
Company's 52-week low was at $1.01
Price action over last quarter: down 40.86%
AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. The company's products under pipeline are ARX-02 and ARX-03. The majority of its revenue is generated from DSUVIA product sales in the United States.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.